Mifepristone is the first and only available glucocorticoid receptor antagonist. It was initially mainly considered as a so-called ‘contragestive’ pill due to its antiprogestin activity. In this review, we summarize the results of mifepristone reported in the literature as a treatment of Cushing’s syndrome. Most of the patients were treated due to unsuccessful surgery and/or partially effective anticortisolic drugs. The majority of them presented a rapid decrease of clinical signs of hypercortisolism during the first month of treatment; about half experienced a reduction in their elevated blood pressure, and half of the diabetic patients presented improved blood glucose levels. Mifepristone treatment has 2 main drawbacks: (1) the blockade of glucocorticoid receptors leads to increased ACTH and cortisol levels, making it difficult to adapt the treatment and diagnose adrenal deficiency, and (2) increased cortisol levels can also lead to severe hypokalemia. Follow-up of efficacy should only be clinical (weight, blood pressure, skin lesions) and biological (regular blood potassium sampling). Dose adjustment will be performed based on these parameters. The lack of a large available prospective cohort of patients on mifepristone, and the scarcity of data on its long-term effects, does not allow recommending it as a first-line drug in the treatment of hypercortisolism. However, as mifepristone is a rapidly effective drug, it can play a role in the management of hypercortisolism. The main indication is the partial efficacy or bad tolerance of other well-known anticortisolic drugs, either by replacement (bad tolerance, lack of effectiveness) or addition (multimodal approach) of mifepristone.

Keywords:
Cushing’s disease, Anticortisolic drug, Ectopic ACTH secretion, Adrenal carcinoma, Bilateral adrenal hyperplasia, Glucocorticoid receptor antagonist
1.
Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M: Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454–2462.
2.
Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T: Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol 2008;158:91–99.
3.
Johanssen S, Allolio B: Mifepristone (ru 486) in Cushing’s syndrome. Eur J Endocrinol 2007;157:561–569.
4.
Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F: The new steroid analog ru 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 1984;59:25–28.
5.
McMaster A, Ray DW: Drug insight: selective agonists and antagonists of the glucocorticoid receptor. Nat Clin Pract 2008;4:91–101.
6.
Miller JW, Crapo L: The medical treatment of Cushing’s syndrome. Endocr Rev 1993;14:443–458.
7.
Beaufrere B, de Parscau L, Chatelain P, Morel Y, Aguercif M, Francois R: Ru 486 administration in a child with Cushing’s syndrome. Lancet 1987;ii:217.
8.
Bilgin YM, van der Wiel HE, Fischer HR, De Herder WW: Treatment of severe psychosis due to ectopic Cushing’s syndrome. J Endocrinol Invest 2007;30:776–779.
9.
Cassier PA, Abou-Amara-Olivieri S, Artru P, Lapalus MG, Riou JP, Lombard-Bohas C: Mifepristone for ectopic acth secretion in metastatic endocrine carcinomas: report of two cases. Eur J Endocrinol 2008;158:935–938.
10.
Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Pico A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B: Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol 2009;160:1003–1010.
11.
Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D: Successful long-term treatment of refractory cushing’s disease with high-dose mifepristone (ru 486). J Clin Endocrinol Metab 2001;86:3568–3573.
12.
Contreras P: Adrenal cancer: tumor regression with ketoconazole or mifepristone (ru 486): in vivo and in vitro evidence supporting tumoral hormone dependency. Proc 69th Ann Endocrine Society Meeting, Indianapolis, 1987, p 23.
13.
Donckier JE, Michel LA, Berbinschi A, De Coster PM, De Plaen JF, Ketelslegers JM, Buysschaert M: Late recurrence of operated adrenocortical carcinoma: atrial natriuretic factor before and after treatment with mitotane. Surgery 1989;105:690–692.
14.
Newfield RS, Spitz IM, Isacson C, New MI: Long-term mifepristone (ru486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol 2001;54:399–404.
15.
Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL: Successful treatment of cushing’s syndrome with the glucocorticoid antagonist ru 486. J Clin Endocrinol Metab 1985;61:536–540.
16.
van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW: Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (ru 486). Ann Intern Med 1991;114:143–144.
17.
Raux-Demay MC, Pierret T, Bouvier d’Yvoire M, Bertagna X, Girard F: Transient inhibition of ru 486 antiglucocorticoid action by dexamethasone. J Clin Endocrinol Metab 1990;70:230–233.
18.
Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM: Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol 1991;35:169–178.
19.
Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B: Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990;70:1426–1430.
20.
Hahner S, Fassnacht M: Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005;6:386–394.
21.
Terzolo M, Angeli A, Fassnacht M, et al: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356:2372–2380.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.